Q1 2025 Lineage Cell Therapeutics Inc Earnings Call Transcript
Key Points
- OpRegen has shown evidence of anatomical and functional benefits lasting up to two years from a one-time surgical delivery, offering a potential advantage over current therapies requiring frequent injections.
- The GAlette Study, run by partners Roche and Genentech, is progressing well, with continuous enrollment and additional clinical sites being opened.
- Lineage Cell Therapeutics Inc (LCTX) has achieved a significant manufacturing milestone, demonstrating the capability to produce millions of doses from a single cell line, which could lead to new partnership opportunities.
- The company's financial position is strong, with a cash position of $47.9 million expected to support operations into Q1 2027.
- Lineage Cell Therapeutics Inc (LCTX) is advancing its OPC1 program for spinal cord injury, with a new delivery device that improves the procedure and plans to enroll the first patient in June.
- There is no timeline available for Genentech's decision to advance OpRegen into a controlled study, creating uncertainty about the program's future development.
- Lineage Cell Therapeutics Inc (LCTX) does not have access to data from the ongoing GAlette Study, limiting their ability to assess progress directly.
- The company's revenue for the quarter was only $1.5 million, indicating limited income from current operations.
- The net loss for the first quarter was $4.1 million, highlighting ongoing financial challenges despite a decrease from the previous year.
- The OPC1 program requires further improvements in delivery and manufacturing before it can move into a later stage trial, indicating potential delays in development.
Welcome to the Lineage Cell Therapeutics first-quarter 2025 conference call. (Operator Instructions) An audio webcast of this call is available on the Investors section of Lineage's website at www.lineagecell.com. This call is subject to copyright and is the property of Lineage, and recordings, reproductions or transmissions of this call without the expressed written consent of Lineage are strictly prohibited. As a reminder, today's call is being recorded. I would now like to introduce your host for today's call, Ioana Hone, Head of Investor Relations at Lineage.
Ms. Hone, please go ahead.
Thank you, Carly. Good afternoon and thank you for joining us. A press release reporting our first-quarter 2025 financial results was issued earlier today, May 13, 2025, and can be found on the Investors section of our website. Please note that today's remarks and responses to your questions reflect management's views as of today only and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
